Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-stage randomised trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer

Trial Profile

A multi-stage randomised trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 25 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Fluorouracil; Mitomycin
  • Indications Adenocarcinoma; Bladder cancer; Carcinoma; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Rad-IO

Most Recent Events

  • 20 Sep 2023 Planned End Date changed from 30 Apr 2028 to 30 Jun 2027.
  • 13 Sep 2021 Planned End Date changed from 1 Dec 2027 to 30 Apr 2028.
  • 12 Mar 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top